A group of dedicated physicians recently came together to send an open letter to the medical journal JAMA. Their purpose: to declare that the recent Ivermectin study published in JAMA was fatally flawed. Note it was this study that suddenly triggered the interest of the mainstream media, from the New York Times to CNN. Prior to this study dozens of clinical trials conducted all over the world that generated positive findings were utterly and completely ignored. TrialSite shares this recent letter.
We the undersigned physicians present this letter to call attention to multiple, integral flaws in the Journal of the American Medical Association’s recently published paper “Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19”. Above all, the data reported do not support the authors’ conclusion that ivermectin is ineffective as a treatment for mild COVID-19.
The study’s flaws span subject population, design, execution and controls. The small sample size (n = 400) had a median age of 37 and a BMI of 26, making them extremely low risk for COVID-19 hard endpoints. Faced with this low-relevance study group, the study authors impro...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).